Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors

Authors:

Abstract
No abstract available
Funding Information
  • Science and Technology Commission of Shanghai Municipality (19411965900)

This publication has 29 references indexed in Scilit: